EFFICACY AND SAFETY OF THE ORAL ANTICOAGULANTS IN THE MANAGEMENT OF VENOUS THROMBOEMBOLISM: INDIRECT COMPARISON
Objective. The aim was to perform an indirect comparisons of the effectiveness and safety of new oral anticoagulants (NOACs) in the management of venous thromboembolism (VTE).Material and methods. In the absence of a head-to-head comparisons, indirect comparison was done using the method proposed by...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2016-12-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/152 |
| _version_ | 1797878939657437184 |
|---|---|
| author | V. I. Petrov O. V. Shatalova V. S. Gorbatenko D. V. Frolov E. A. Ponomarev A. S. Maslakov |
| author_facet | V. I. Petrov O. V. Shatalova V. S. Gorbatenko D. V. Frolov E. A. Ponomarev A. S. Maslakov |
| author_sort | V. I. Petrov |
| collection | DOAJ |
| description | Objective. The aim was to perform an indirect comparisons of the effectiveness and safety of new oral anticoagulants (NOACs) in the management of venous thromboembolism (VTE).Material and methods. In the absence of a head-to-head comparisons, indirect comparison was done using the method proposed by Butcher et al.Results. The indirect comparison included 5 RCTs. Apixaban, rivaroxaban and dabigatran were equally effective in preventing recurrent symptomatic VTE, deep vein thrombosis and pulmonary embolism. Dabigatran increased major bleeding risk compared to apixaban RR=2.36; 95% CI 1.15-4.82 and the risk major or clinical relevant non-major (CRNM) bleedings RR=1.43; 95% CI 1.06-1.93. Dabigatran and apixaban were associated with the significant lower risk of major and CRNM bleeding compared with rivaroxaban RR=1.49; 95% CI 1.17-1.91 and RR=2.13; 95% CI 1.66-2.74.Conclusions. There were no statistically significant differences between apixaban, dabigatran and rivaroxaban in effectiveness. Apixaban treatment associated with the most favorable safety profile of the NOACs. |
| first_indexed | 2024-04-10T02:39:59Z |
| format | Article |
| id | doaj.art-5d246c3116144661b1581fa64734c58e |
| institution | Directory Open Access Journal |
| issn | 2070-4909 2070-4933 |
| language | Russian |
| last_indexed | 2024-04-10T02:39:59Z |
| publishDate | 2016-12-01 |
| publisher | IRBIS LLC |
| record_format | Article |
| series | Фармакоэкономика |
| spelling | doaj.art-5d246c3116144661b1581fa64734c58e2023-03-13T07:48:15ZrusIRBIS LLCФармакоэкономика2070-49092070-49332016-12-01933710.17749/2070-4909.2016.9.3.003-007133EFFICACY AND SAFETY OF THE ORAL ANTICOAGULANTS IN THE MANAGEMENT OF VENOUS THROMBOEMBOLISM: INDIRECT COMPARISONV. I. Petrov0O. V. Shatalova1V. S. Gorbatenko2D. V. Frolov3E. A. Ponomarev4A. S. Maslakov5Volgograd State Medical University of the Ministry of Health Russian FederationVolgograd State Medical University of the Ministry of Health Russian FederationVolgograd State Medical University of the Ministry of Health Russian FederationVolgograd State Medical University of the Ministry of Health Russian FederationVolgograd State Medical University of the Ministry of Health Russian FederationVolgograd State Medical University of the Ministry of Health Russian FederationObjective. The aim was to perform an indirect comparisons of the effectiveness and safety of new oral anticoagulants (NOACs) in the management of venous thromboembolism (VTE).Material and methods. In the absence of a head-to-head comparisons, indirect comparison was done using the method proposed by Butcher et al.Results. The indirect comparison included 5 RCTs. Apixaban, rivaroxaban and dabigatran were equally effective in preventing recurrent symptomatic VTE, deep vein thrombosis and pulmonary embolism. Dabigatran increased major bleeding risk compared to apixaban RR=2.36; 95% CI 1.15-4.82 and the risk major or clinical relevant non-major (CRNM) bleedings RR=1.43; 95% CI 1.06-1.93. Dabigatran and apixaban were associated with the significant lower risk of major and CRNM bleeding compared with rivaroxaban RR=1.49; 95% CI 1.17-1.91 and RR=2.13; 95% CI 1.66-2.74.Conclusions. There were no statistically significant differences between apixaban, dabigatran and rivaroxaban in effectiveness. Apixaban treatment associated with the most favorable safety profile of the NOACs.https://www.pharmacoeconomics.ru/jour/article/view/152indirect comparisonnew oral anticoagulantsvenous thromboembolismrivaroxabanapixabandabigatran |
| spellingShingle | V. I. Petrov O. V. Shatalova V. S. Gorbatenko D. V. Frolov E. A. Ponomarev A. S. Maslakov EFFICACY AND SAFETY OF THE ORAL ANTICOAGULANTS IN THE MANAGEMENT OF VENOUS THROMBOEMBOLISM: INDIRECT COMPARISON Фармакоэкономика indirect comparison new oral anticoagulants venous thromboembolism rivaroxaban apixaban dabigatran |
| title | EFFICACY AND SAFETY OF THE ORAL ANTICOAGULANTS IN THE MANAGEMENT OF VENOUS THROMBOEMBOLISM: INDIRECT COMPARISON |
| title_full | EFFICACY AND SAFETY OF THE ORAL ANTICOAGULANTS IN THE MANAGEMENT OF VENOUS THROMBOEMBOLISM: INDIRECT COMPARISON |
| title_fullStr | EFFICACY AND SAFETY OF THE ORAL ANTICOAGULANTS IN THE MANAGEMENT OF VENOUS THROMBOEMBOLISM: INDIRECT COMPARISON |
| title_full_unstemmed | EFFICACY AND SAFETY OF THE ORAL ANTICOAGULANTS IN THE MANAGEMENT OF VENOUS THROMBOEMBOLISM: INDIRECT COMPARISON |
| title_short | EFFICACY AND SAFETY OF THE ORAL ANTICOAGULANTS IN THE MANAGEMENT OF VENOUS THROMBOEMBOLISM: INDIRECT COMPARISON |
| title_sort | efficacy and safety of the oral anticoagulants in the management of venous thromboembolism indirect comparison |
| topic | indirect comparison new oral anticoagulants venous thromboembolism rivaroxaban apixaban dabigatran |
| url | https://www.pharmacoeconomics.ru/jour/article/view/152 |
| work_keys_str_mv | AT vipetrov efficacyandsafetyoftheoralanticoagulantsinthemanagementofvenousthromboembolismindirectcomparison AT ovshatalova efficacyandsafetyoftheoralanticoagulantsinthemanagementofvenousthromboembolismindirectcomparison AT vsgorbatenko efficacyandsafetyoftheoralanticoagulantsinthemanagementofvenousthromboembolismindirectcomparison AT dvfrolov efficacyandsafetyoftheoralanticoagulantsinthemanagementofvenousthromboembolismindirectcomparison AT eaponomarev efficacyandsafetyoftheoralanticoagulantsinthemanagementofvenousthromboembolismindirectcomparison AT asmaslakov efficacyandsafetyoftheoralanticoagulantsinthemanagementofvenousthromboembolismindirectcomparison |